New PET scan could spot leftover prostate cancer after targeted treatment
NCT ID NCT07568756
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial will test whether a special PET scan using Flotufolastat F18 can accurately detect any remaining prostate cancer after focal therapy (like cryotherapy or HIFU). About 60 men with prostate cancer who haven't had prior treatment will get the scan before and after their focal therapy. The results will be compared to standard MRI and biopsy to see if the PET scan is a reliable way to confirm successful treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flotufolastat F18 (a radioactive tracer used in PET scans)
What this could lead to
If successful, this could provide a more accurate way to check if focal therapy has fully treated prostate cancer, potentially reducing the need for repeat biopsies.
What could go wrong
This is a small, early-phase study (60 participants) focused on diagnostic accuracy, not treatment. The tracer may not prove reliable enough to replace current methods, and results may not apply to all prostate cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••